LONGEVERON INC-A (LGVN) Stock Fundamental Analysis

NASDAQ:LGVN • US54303L2034

0.5751 USD
+0.02 (+2.7%)
At close: Feb 20, 2026
0.565 USD
-0.01 (-1.76%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LGVN. LGVN was compared to 520 industry peers in the Biotechnology industry. The financial health of LGVN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, LGVN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • LGVN had negative earnings in the past year.
  • LGVN had a negative operating cash flow in the past year.
  • LGVN had negative earnings in each of the past 5 years.
  • In the past 5 years LGVN always reported negative operating cash flow.
LGVN Yearly Net Income VS EBIT VS OCF VS FCFLGVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • The Return On Assets of LGVN (-137.18%) is worse than 82.15% of its industry peers.
  • The Return On Equity of LGVN (-214.14%) is worse than 68.91% of its industry peers.
Industry RankSector Rank
ROA -137.18%
ROE -214.14%
ROIC N/A
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
LGVN Yearly ROA, ROE, ROICLGVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • LGVN has a Gross Margin of 74.88%. This is amongst the best in the industry. LGVN outperforms 83.88% of its industry peers.
  • In the last couple of years the Gross Margin of LGVN has grown nicely.
  • The Profit Margin and Operating Margin are not available for LGVN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
LGVN Yearly Profit, Operating, Gross MarginsLGVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • LGVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LGVN has more shares outstanding
  • LGVN has more shares outstanding than it did 5 years ago.
  • LGVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LGVN Yearly Shares OutstandingLGVN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M
LGVN Yearly Total Debt VS Total AssetsLGVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • LGVN has an Altman-Z score of -14.33. This is a bad value and indicates that LGVN is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -14.33, LGVN is doing worse than 79.27% of the companies in the same industry.
  • LGVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.33
ROIC/WACCN/A
WACC8.72%
LGVN Yearly LT Debt VS Equity VS FCFLGVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • LGVN has a Current Ratio of 2.09. This indicates that LGVN is financially healthy and has no problem in meeting its short term obligations.
  • LGVN's Current ratio of 2.09 is on the low side compared to the rest of the industry. LGVN is outperformed by 74.86% of its industry peers.
  • A Quick Ratio of 2.09 indicates that LGVN has no problem at all paying its short term obligations.
  • LGVN has a worse Quick ratio (2.09) than 72.74% of its industry peers.
Industry RankSector Rank
Current Ratio 2.09
Quick Ratio 2.09
LGVN Yearly Current Assets VS Current LiabilitesLGVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 76.27% over the past year.
  • Looking at the last year, LGVN shows a very negative growth in Revenue. The Revenue has decreased by -22.41% in the last year.
  • The Revenue for LGVN have been decreasing by -15.76% on average. This is quite bad
EPS 1Y (TTM)76.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.71%
Revenue 1Y (TTM)-22.41%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%-82.28%

3.2 Future

  • The Earnings Per Share is expected to grow by 16.91% on average over the next years. This is quite good.
  • Based on estimates for the next years, LGVN will show a very strong growth in Revenue. The Revenue will grow by 74.82% on average per year.
EPS Next Y64.14%
EPS Next 2Y29.67%
EPS Next 3Y16.91%
EPS Next 5YN/A
Revenue Next Year-47.8%
Revenue Next 2Y-43.23%
Revenue Next 3Y74.82%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LGVN Yearly Revenue VS EstimatesLGVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
LGVN Yearly EPS VS EstimatesLGVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • LGVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LGVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LGVN Price Earnings VS Forward Price EarningsLGVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LGVN Per share dataLGVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LGVN's earnings are expected to grow with 16.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.67%
EPS Next 3Y16.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for LGVN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LONGEVERON INC-A

NASDAQ:LGVN (2/20/2026, 8:00:01 PM)

After market: 0.565 -0.01 (-1.76%)

0.5751

+0.02 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-06
Inst Owners8.67%
Inst Owner Change-9.85%
Ins Owners8.82%
Ins Owner Change-0.81%
Market Cap12.27M
Revenue(TTM)1.44M
Net Income(TTM)-21.34M
Analysts82.5
Price Target7 (1117.18%)
Short Float %7.63%
Short Ratio4.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.86%
Min EPS beat(2)-49.94%
Max EPS beat(2)8.22%
EPS beat(4)1
Avg EPS beat(4)-16.87%
Min EPS beat(4)-49.94%
Max EPS beat(4)8.22%
EPS beat(8)3
Avg EPS beat(8)-18.04%
EPS beat(12)3
Avg EPS beat(12)-16.17%
EPS beat(16)5
Avg EPS beat(16)-11.14%
Revenue beat(2)0
Avg Revenue beat(2)-39.57%
Min Revenue beat(2)-52.82%
Max Revenue beat(2)-26.32%
Revenue beat(4)0
Avg Revenue beat(4)-31.04%
Min Revenue beat(4)-52.82%
Max Revenue beat(4)-7.27%
Revenue beat(8)2
Avg Revenue beat(8)140.83%
Revenue beat(12)2
Avg Revenue beat(12)81.18%
Revenue beat(16)5
Avg Revenue beat(16)72.18%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.54
P/FCF N/A
P/OCF N/A
P/B 1.23
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-1.49
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.07
BVpS0.47
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -137.18%
ROE -214.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.88%
FCFM N/A
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
F-Score4
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 54.96%
Cap/Sales 45.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.09
Quick Ratio 2.09
Altman-Z -14.33
F-Score4
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)90.92%
Cap/Depr(5y)89.88%
Cap/Sales(3y)69.8%
Cap/Sales(5y)62.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.71%
EPS Next Y64.14%
EPS Next 2Y29.67%
EPS Next 3Y16.91%
EPS Next 5YN/A
Revenue 1Y (TTM)-22.41%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%-82.28%
Revenue Next Year-47.8%
Revenue Next 2Y-43.23%
Revenue Next 3Y74.82%
Revenue Next 5YN/A
EBIT growth 1Y-25.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.41%
OCF growth 3YN/A
OCF growth 5YN/A

LONGEVERON INC-A / LGVN FAQ

What is the ChartMill fundamental rating of LONGEVERON INC-A (LGVN) stock?

ChartMill assigns a fundamental rating of 3 / 10 to LGVN.


Can you provide the valuation status for LONGEVERON INC-A?

ChartMill assigns a valuation rating of 0 / 10 to LONGEVERON INC-A (LGVN). This can be considered as Overvalued.


How profitable is LONGEVERON INC-A (LGVN) stock?

LONGEVERON INC-A (LGVN) has a profitability rating of 1 / 10.


How financially healthy is LONGEVERON INC-A?

The financial health rating of LONGEVERON INC-A (LGVN) is 5 / 10.